Androgen News and Research

RSS

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

News outlets offer a variety of stories about Medicare, including details of a new bidding process for medical equipment and the scheduled cut in physician reimbursement.

8 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

When Medicare policy changes led to reductions in reimbursement for hormonal treatment of prostate cancer, there was a sharp decline in its use among patients not likely to benefit from the treatment. But among patients for whom the therapy is clearly beneficial, doctors continued to prescribe it at the same rate, according to a new study.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

Enzon Pharmaceuticals, Inc. today announced that it has been awarded $1.2 million in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

3 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

21 Oct 2010

Female sex hormones help women survive after trauma

Women who have been severely injured are 14 percent more likely to survive than similarly injured men, according to a new Johns Hopkins study, a difference researchers believe may be due to the negative impact of male sex hormones on a traumatized immune system.

21 Oct 2010

FDA asks manufacturers to add new warnings to labeling of prostate cancer drugs

The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.

21 Oct 2010

Study reveals sex hormones can influence structure and function of heart's right ventricle

In the largest human study to date on the topic, researchers have uncovered evidence of the possible influence of human sex hormones on the structure and function of the right ventricle (RV) of the heart.

20 Oct 2010

Tips to improve cellular prostate health

Prostate cancer is one of the most common cancers in America and may lead to more than 32,000 deaths this year. Medical Doctor and cancer expert, Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer.

19 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

Androgen News and Research

Medicare announces contracts for competitive bidding on equipment while docs worry about payment cuts

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Combination of radiation and hormone therapy improves survival rate among prostate cancer patients

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Female sex hormones help women survive after trauma

FDA asks manufacturers to add new warnings to labeling of prostate cancer drugs

Study reveals sex hormones can influence structure and function of heart's right ventricle

Tips to improve cellular prostate health

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

CDC, national leaders issue recommendations to standardize testosterone tests

Abiraterone Phase III clinical data to be presented at ESMO meeting

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Researchers find radical prostatectomy provides high survival rates

OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer

New study signals hope for treatment of rare neurodegenerative disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News